Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
EU Okays CV Benefit Labeling for Canagliflozin in DiabetesThe European label for the SGLT2 inhibitor canagliflozin for type 2 diabetes will now include positive cardiovascular benefit results from the CANVAS trial, while a decision from the US FDA is forthcoming.
Medscape Medical News, September 2018
HYP 2018Lifestyle Change Curbs Need for Antihypertensive AgentsLifestyle interventions can reduce the need for antihypertensive medications in men and women with elevated blood pressure, a finding that supports the new hypertension guidelines, researchers say.
Beta-Blockade After MI: No Practice Should Be Set in StoneMeta-analyses suggest little benefit for beta-blockers in contemporary patients with normal ejection fraction after MI. What other dogma should be revisited in light of an evolving evidence base?
A Transformation in Stroke CareDEFUSE-3 supports a longer window for endovascular treatment of acute ischemic stroke. Plus, problematic recommendations from new stroke guidelines.
Medscape Neurology, February 13, 2018
Dosing at Night to Cause BP 'Dipping'Prescribing short-term blood pressure medication could help patients achieve 'dips' overnight and reduce their risk for cardiovascular events, reports Dr George Bakris.
